Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Sales and Divestitures: 2020-2024

  • Relay Therapeutics' Gains from Sales and Divestitures rose 140.52% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year increase of 140.52%. This contributed to the annual value of $2.1 million for FY2024, which is 140.52% up from last year.
  • Per Relay Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $2.1 million for Q4 2024, which was up 140.52% from $883,652 recorded in Q4 2023.
  • In the past 5 years, Relay Therapeutics' Gains from Sales and Divestitures ranged from a high of $2.1 million in Q4 2024 and a low of $84,489 during Q4 2021.
  • For the 3-year period, Relay Therapeutics' Gains from Sales and Divestitures averaged around $1.1 million, with its median value being $883,652 (2023).
  • In the last 5 years, Relay Therapeutics' Gains from Sales and Divestitures crashed by 85.43% in 2021 and then skyrocketed by 371.46% in 2022.
  • Over the past 5 years, Relay Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $579,825 in 2020, then plummeted by 85.43% to $84,489 in 2021, then spiked by 371.46% to $398,330 in 2022, then skyrocketed by 121.84% to $883,652 in 2023, then spiked by 140.52% to $2.1 million in 2024.
  • Its Gains from Sales and Divestitures was $2.1 million in Q4 2024, compared to $883,652 in Q4 2023 and $398,330 in Q4 2022.